Acute Crit Care.  2022 May;37(2):151-158. 10.4266/acc.2022.00619.

Review of remimazolam and sedatives in the intensive care unit

• Choi HR
• Song IA

• KMID: 2531671
• DOI: http://doi.org/10.4266/acc.2022.00619

Abstract

Remimazolam is a novel intravenous ultra-short acting benzodiazepine that has the potential of being a safe and effective new sedative for use in intensive care unit (ICU) settings. Because remimazolam metabolizes rapidly by being hydrolyzed to an inactive metabolite (CNS 7054) through non-specific tissue esterase activity, specific dosing adjustment for older adults and for patients with renal or hepatic impairment patients (except for those with severe hepatic impairment) is not required. In addition, research has shown that remimazolam may be reversed by administration of flumazenil, as its half time was sufficiently short compared to flumazenil. It shows a lower incidence of cardiorespiratory depression, less injection pain, and no fatal complications such as propofol infusion syndrome and malignant hyperthermia of inhalational anesthetics. Future studies to study the suitability of remimazolam for managing the sedation of ICU patients who need sedation for a long time over several days is required.

Keyword

cricial care; midazolam; flumazenil; remimazolam

Reference

1. Keam SJ. Remimazolam: first approval. Drugs. 2020; 80:625–33.

2. Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! J Anesth. 2020; 34:479–82.

3. Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent. Front Pharmacol. 2021; 12:690875.

4. Burry L, Rose L, McCullagh IJ, Fergusson DA, Ferguson ND, Mehta S. Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation. Cochrane Database Syst Rev. 2014; 2014:CD009176.

5. Brush DR, Kress JP. Sedation and analgesia for the mechanically ventilated patient. Clin Chest Med. 2009; 30:131–41.

6. DAS-Taskforce 2015, Baron R, Binder A, Biniek R, Braune S, Buerkle H, et al. Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine: revision 2015 (DAS-Guideline 2015)-short version. Ger Med Sci. 2015; 13:Doc19.

7. Martin J, Parsch A, Franck M, Wernecke KD, Fischer M, Spies C. Practice of sedation and analgesia in German intensive care units: results of a national survey. Crit Care. 2005; 9:R117–23.

8. Meiser A, Laubenthal H. Inhalational anaesthetics in the ICU: theory and practice of inhalational sedation in the ICU, economics, risk-benefit. Best Pract Res Clin Anaesthesiol. 2005; 19:523–38.

9. Shinotsuka CR, Salluh JI. Perceptions and practices regarding delirium, sedation and analgesia in critically ill patients: a narrative review. Rev Bras Ter Intensiva. 2013; 25:155–61.

10. Schweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care. 2008; 12(Suppl 3):S6.

11. Kress JP, Pohlman AS, Hall JB. Sedation and analgesia in the intensive care unit. Am J Respir Crit Care Med. 2002; 166:1024–8.

12. Temesgen N, Chekol B, Tamirie T, Eshetie D, Simeneh N, Feleke A. Adult sedation and analgesia in a resource limited intensive care unit: a systematic review and evidence based guideline. Ann Med Surg (Lond). 2021; 66:102356.

13. Barr J. Propofol: a new drug for sedation in the intensive care unit. Int Anesthesiol Clin. 1995; 33:131–54.

14. Hall RI, Sandham D, Cardinal P, Tweeddale M, Moher D, Wang X, et al. Propofol vs midazolam for ICU sedation : a Canadian multicenter randomized trial. Chest. 2001; 119:1151–9.

15. Zorrilla-Vaca A, Arevalo JJ, Escandón-Vargas K, Soltanifar D, Mirski MA. Infectious disease risk associated with contaminated propofol anesthesia, 1989-2014(1). Emerg Infect Dis. 2016; 22:981–92.

16. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med. 1995; 333:147–54.

17. Mirrakhimov AE, Voore P, Halytskyy O, Khan M, Ali AM. Propofol infusion syndrome in adults: a clinical update. Crit Care Res Pract. 2015; 2015:260385.

18. Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007; 62:690–701.

19. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med. 1998; 26:947–56.

20. Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995; 346:145–7.

21. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 1994; 73:658–61.

22. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007; 298:2644–53.

23. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009; 301:489–99.

24. Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012; 307:1151–60.

25. Reade MC, Eastwood GM, Bellomo R, Bailey M, Bersten A, Cheung B, et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA. 2016; 315:1460–8.

26. Skrobik Y, Duprey MS, Hill NS, Devlin JW. Low-dose nocturnal dexmedetomidine prevents ICU delirium: a randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2018; 197:1147–56.

27. Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care. 2010; 14:R38.

28. Kawazoe Y, Miyamoto K, Morimoto T, Yamamoto T, Fuke A, Hashimoto A, et al. Effect of dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical trial. JAMA. 2017; 317:1321–8.

29. Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med. 2009; 37:3031–9.

30. Shehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, et al. Early sedation with dexmedetomidine in critically ill patients. N Engl J Med. 2019; 380:2506–17.

31. Jalowiecki P, Rudner R, Gonciarz M, Kawecki P, Petelenz M, Dziurdzik P. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology. 2005; 103:269–73.

32. Scott-Warren VL, Sebastian J. Dexmedetomidine: its use in intensive care medicine and anaesthesia. BJA Educ. 2016; 16:242–6.

33. Jerath A, Parotto M, Wasowicz M, Ferguson ND. Volatile anesthetics: is a new player emerging in critical care sedation? Am J Respir Crit Care Med. 2016; 193:1202–12.

34. Kim HY, Lee JE, Kim HY, Kim J. Volatile sedation in the intensive care unit: a systematic review and meta-analysis. Medicine (Baltimore). 2017; 96:e8976.

35. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015; 10:93.

36. Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth. 2014; 8:388–91.

37. Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD. Remimazolam: pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy. 2016; 36:1021–7.

38. Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012; 115:284–96.

39. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012; 115:274–83.

40. Schüttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers. Part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology. 2020; 132:636–51.

41. Birgenheier NM, Stuart AR, Egan TD. Soft drugs in anesthesia: remifentanil as prototype to modern anesthetic drug development. Curr Opin Anaesthesiol. 2020; 33:499–505.

42. Stafford JA, Pacofsky GJ, Cox RF, Cowan JR, Dorsey GF Jr, Gonzales SS, et al. Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2002; 12:3215–8.

43. Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: a novel ultra-short-acting Benzodiazepine. Anesthesiology. 2007; 107:60–6.

44. Nakanishi T, Sento Y, Kamimura Y, Tsuji T, Kako E, Sobue K. Remimazolam for induction of anesthesia in elderly patients with severe aortic stenosis: a prospective, observational pilot study. BMC Anesthesiol. 2021; 21:306.

45. Stöhr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021; 127:415–23.

46. Pambianco DJ, Cash BD. New horizons for sedation: the ultrashort acting benzodiazepine remimazolam. Tech Gastrointest Endosc. 2016; 18:22–8.

47. Zhou J, Leonowens C, Ivaturi VD, Lohmer LL, Curd L, Ossig J, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth. 2020; 66:109899.

48. Zinderman CE, Landow L, Wise RP. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg. 2006; 43:1004–9.

49. Sasaki H, Hoshijima H, Mizuta K. Ringer’s acetate solution-induced precipitation of remimazolam. Br J Anaesth. 2021; 126:e87–9.

50. Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth. 2021; 35:322.

51. Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018; 88:427–37.

52. Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020; 33:506–11.

53. Pastis NJ, Yarmus LB, Schippers F, Ostroff R, Chen A, Akulian J, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest. 2019; 155:137–46.

54. Rex DK, Bhandari R, Lorch DG, Meyers M, Schippers F, Bernstein D. Safety and efficacy of remimazolam in high risk colonoscopy: a randomized trial. Dig Liver Dis. 2021; 53:94–101.

55. Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, et al. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015; 120:771–80.

56. Chen SH, Yuan TM, Zhang J, Bai H, Tian M, Pan CX, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol. 2021; 36:474–81.

57. Zhu X, Wang H, Yuan S, Li Y, Jia Y, Zhang Z, et al. Efficacy and safety of remimazolam in endoscopic sedation: a systematic review and meta-analysis. Front Med (Lausanne). 2021; 8:655042.

58. Lee A, Shirley M. Remimazolam: a review in procedural sedation. Drugs. 2021; 81:1193–201.

59. Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020; 34:543–53.

60. Sneyd JR, Gambus PL, Rigby-Jones AE. Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam: a narrative review. Br J Anaesth. 2021; 127:41–55.

61. Whizar-Lugo V, Garnica-Camacho C, Gastelum-Dagnino R. Remimazolam: a new ultra short acting benzodiazepine. J Anesth Crit Care. 2016; 4:1–5.

62. de Nantes CH. REmimazolam infusion in the context of hypnotic shortage in the critical care unit during the pandemic of COVID-19: the non-randomized, non-controlled, pilot, open, mono-centric REHSCU study. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2000 [cited 2022 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04611425.